Daré Bioscience, Inc.
DARE
$1.92
$0.073.78%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 500.39% | 1,709.59% | -94.48% | -194.64% | 173.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 500.39% | 1,709.59% | -94.48% | -194.64% | 173.12% |
| Cost of Revenue | -60.70% | 58.04% | -56.18% | -- | -31.65% |
| Gross Profit | 66.98% | -48.42% | 55.57% | -194.64% | 32.22% |
| SG&A Expenses | -2.62% | -20.99% | 22.43% | -2.87% | -13.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.59% | -53.14% | -22.20% | -48.43% | -23.63% |
| Operating Income | 34.54% | 72.69% | 21.56% | 47.99% | 23.93% |
| Income Before Tax | 31.48% | 73.82% | 24.24% | -131.11% | 35.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.48% | 73.82% | 24.24% | -131.11% | 35.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.48% | 73.82% | 24.24% | -131.11% | 35.19% |
| EBIT | 34.54% | 72.69% | 21.56% | 47.99% | 23.93% |
| EBITDA | 44.52% | 82.59% | 31.71% | 54.14% | 26.72% |
| EPS Basic | 58.67% | 85.30% | 49.31% | -129.50% | 38.02% |
| Normalized Basic EPS | 58.67% | 85.30% | 49.30% | -129.50% | 38.03% |
| EPS Diluted | 58.67% | 70.69% | 49.18% | -129.79% | 38.02% |
| Normalized Diluted EPS | 58.67% | 85.30% | 49.30% | -129.73% | 38.03% |
| Average Basic Shares Outstanding | 65.80% | 78.14% | 49.46% | 5.47% | 4.57% |
| Average Diluted Shares Outstanding | 65.80% | 78.14% | 49.46% | 4.66% | 4.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |